OPtain120 targets blood pressure, while Chalcurb targets visceral fat.
Ingredient distributor Horn (La Mirada, CA) is now exclusively distributing two ingredients for heart health and weight management in North America.
Targeting blood pressure management, OPtain120 is a patented combination of onion and pumpkin extract. Horn says that OPtain120 lowered systolic blood pressure (6%) and diastolic blood pressure (4%) in as little as five days, as shown by clinical trials conducted in the United States and Japan.
The ingredient is an angiotensin-converting-enzyme (ACE) inhibitor, suppressing the production of angiotensin II. This decreases peripheral resistance and blood volume, thereby reducing blood pressure. OPtain120 also boosts nitric oxide production, thereby increasing the diameter of the blood vessels and reducing blood pressure. Japanese company Ryusendo manufactures the ingredient.
Designed to target the visceral fat (abdominal fat tucked in between the internal organs) linked to increased risk of diabetes and heart disease, Chalcurb is derived from the dried sap of the Ashitaba plant (Angelica keiskei) and is manufactured by Japan Bio Science Laboratory. Horn says two clinical studies show the ingredient’s ability to reduce visceral fat by 10% in just eight weeks. The ingredient supports the production of leptin and adiponectin, which influences satiety, lipid metabolism, and glucose regulation. In addition, subjects saw reductions in subcutaneous fat, weight, body mass index (BMI), and waist and hip circumference.
In a press release, Xiaoming Chien, PhD, vice president of Horn Nutraceuticals, called OPtain120 and ChalCurb ingredients that address “two health topics that are dramatically affecting the majority of the adults in the United States today.”
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Photo © iStockphoto.com/under_score
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.